ArticleBMC genomics2025
Epigenetic modifications in the murine liver upon depletion of transcriptional coregulator host cell factor 1.
Article in BMC genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTranscriptional co-regulators fine-tune gene expression by modulating transcription factor activity and chromatin dynamics. HCF-1 (Host Cell Factor 1), a conserved transcriptional co-regulator, has been implicated in cell cycle progression, liver metabolism, and regeneration. Loss of hepatocyte-specific HCF-1 in mice leads to spontaneous NAFLD, which rapidly exacerbates to NASH and compromises liver regeneration. While its role in transcriptional regulation is well-established, the impact of HCF-1 on epigenetic modifications remains relatively unexplored.
methodsTo investigate the consequences of HCF-1 depletion, we performed histological and biochemical analyses of murine livers, assessing liver injury, lipid accumulation, and hepatocyte proliferation upon 2/3 partial hepatectomy (PH). Additionally, we conducted RNA sequencing (RNA-seq) and chromatin immunoprecipitation sequencing (ChIP-seq) for H3K4me3 and RNA polymerase II (POL2) to examine the epigenetic and transcriptional alterations associated with HCF-1 loss.
resultsLoss of HCF-1 results in severe liver injury, causing hallmark features of NAFLD, including steatosis, inflammation, fibrosis, and mitochondrial dysfunction. Following injury, hepatocytes typically re-enter the cell cycle to replenish lost cells. However, in the absence of HCF-1, hepatocytes fail to proliferate leading to a progressive decline in liver function. Even upon 2/3 PH, HCF-1-deficient hepatocytes remain arrested in the cell cycle, further exacerbating disease severity and preventing tissue regeneration. RNA-seq analyses revealed significant downregulation of genes involved in cell cycle progression, metabolism, and mitochondrial structure and function including those regulating oxidative phosphorylation. ChIP-seq data showed altered H3K4me3 patterns at promoter and enhancer regions of key hepatic genes. These findings indicate that HCF-1 is essential for maintaining transcriptional and epigenetic landscapes necessary for hepatocyte proliferation and regeneration.
conclusionsOur study establishes HCF-1 as a critical regulator of hepatic homeostasis, with roles extending beyond transcriptional control to epigenetic regulation of liver function and repair. Loss of HCF-1 not only induces liver injury and NAFLD but also prevents hepatocyte proliferation, impairing regeneration and accelerating disease progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.